

Combination Antifungal Therapy: When is Two Better Than One?

By Linsey McPheeters, Pharm.D.

References

1. Vasquez JA. Combination antifungal therapy against *Candida* species: the new frontier— are we there yet? *Medical Mycology* 2003;41:355-68.
2. Mukherjee PK, Sheehan DJ, Hitchcock CA, et al. Combination treatment of invasive fungal infections. *Clinical Microbiology Reviews* 2005;18(1):163-94.
3. Klasco RK (Ed). DRUGDEX® System (electronic version). Thomson Micromedex, Greenwood Village, Colorado, USA. Available at: <http://www.thomsonhc.com> (Last accessed: 5/24/2005).
 - a. Miconazole - Drug Evaluation (*Clinical Applications: Mechanis of Action/ Pharmacology*).
 - b. Clotrimazole - Drug Evaluation (*Clinical Applications: Mechanis of Action/ Pharmacology*).
 - c. Ketoconazole - Drug Evaluation (*Clinical Applications: Mechanis of Action/ Pharmacology*).
 - d. Itraconazole - Drug Evaluation (*Clinical Applications: Mechanis of Action/ Pharmacology*).
 - e. Fluconazole - Drug Evaluation (*Clinical Applications: Mechanis of Action/ Pharmacology*).
 - f. Voriconazole - Drug Evaluation (*Clinical Applications: Mechanis of Action/ Pharmacology*).
 - g. Amphotericin B - Drug Evaluation (*Clinical Applications: Mechanis of Action/ Pharmacology*).
 - h. Flucytosine - Drug Evaluation (*Clinical Applications: Mechanis of Action/ Pharmacology*).
 - i. Caspofungin - Drug Evaluation (*Clinical Applications: Mechanis of Action/ Pharmacology*).
4. Marr K. Combination antifungal therapy: where are we now, and where are we going? *Oncology* 2004;18(13):S24-29.
5. Kontoyiannis DP, Lewis RE. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. *Drug Resistance Updates* 2003;6:257-69.
6. Cuenca-Estrella M. Combinations of antifungal agents in therapy— what value are they? *Journal of Antimicrobial Chemotherapy* 2004;54:854-69.
7. Franzot SP, Casadevall A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against *Cryptococcus neoformans in vitro*. *Antimicrobial Agents and Chemotherapy*. 1997;41(2):331-36.
8. Ernst EJ, Yodoi K, Roling EE, et al. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against *Candida lusitanae* determined by microdilution, e-test, and time-kill methods. *Antimicrobial Agents and Chemotherapy* 2002;46(2):578-81.
9. Rodero L, Córdoba S, Cahn P, et al. *In vitro* susceptibility studies of *Cryptococcus neoformans* isolated from patients with no clinical response to amphotericin B therapy. *Journal of Antimicrobial Chemotherapy* 2000;45:239-42.

(Continued on page 2)

A University of Washington Drug Information Center publication
Distributed monthly by authority of the Pharmacy and Therapeutics Committee
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.
Department of Pharmacy Services / School of Pharmacy

Copyright © 2005 by the University of Washington
Also published on the World Wide Web at <http://uw.prnrx.org/therapyTopics.asp>
No material may be reproduced in whole or in part without written permission from the editor.

References (continued)

10. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. *Clinical Infectious Diseases* 2003;36:1221-28.
11. Girmenia C, Venditti M, Martino P. Fluconazole in combination with flucytosine in the treatment of fluconazole-resistant *Candida* infections. *Diagnostic Microbiology and Infectious Disease* 2003;46:227-31.
12. Saag MS, Graybill JR, Larson RA, et al. Practice Guidelines for the Management of Cryptococcal Disease. *Clinical Infectious Diseases* 2000;30:710-18.
13. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. *The New England Journal of Medicine* 1979;301(3):126-31.
14. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. *The New England Journal of Medicine* 1997;337(1):15-21.
15. Chuch SL, Sande MA. Infections with *Cryptococcus neoformans* in the acquired immunodeficiency syndrome. *The New England Journal of Medicine* 1989;321(12):794-99.
16. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. *Clinical Infectious Diseases* 2004;39:797-802.
17. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory *Aspergillus* pneumonia in patients with acute leukemia. *Cancer* 2003;97(4):1025-32.
18. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematological malignancies. *Cancer* 2003;98(2):292-99.
19. Arikan S, Lozano-Chiu M, Paetznick V, et al. *In vitro* synergy of caspofungin and amphotericin B against *Aspergillus* and *Fusarium* spp. *Antimicrobial Agents and Chemotherapy* 2002;46(1):245-47.
20. Barchiesi F, Gallo D, Caselli F, et al. In-vitro interactions of itraconazole with flucytosine against clinical isolates of *Cryptococcus neoformans*. *Journal of Antimicrobial Chemotherapy* 1999;44:65-70.
21. Barchiesi F, Schimizzi AM, Caselli F, et al. Interactions between triazoles and amphotericin B against *Cryptococcus neoformans*. *Antimicrobial Agents and Chemotherapy* 2000;44(9):2435-41.
22. Barchiesi F, Spreghini E, Maracci M, et al. In vitro activities of voriconazole in combination with three other antifungal agents against *Candida glabrata*. *Antimicrobial Agents and Chemotherapy* 2004;48(9):3317-22.
23. Dannaoui E, Lortholary O, and Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against *Aspergillus fumigatus* and *Aspergillus terreus*. *Antimicrobial Agents and Chemotherapy* 2004;48(3):970-78.
24. Denning DW, Hanson LH, Perlman AM, et al. In vitro susceptibility and synergy studies of *Aspergillus* species to conventional and new agents. *Diagn Microbiol Infect Dis* 1992;15:21-34.
25. Lewis RE, Diekema DJ, Messer SA, et al. Comparison of Etest, checkerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against *Candida* species. *Journal of Antimicrobial Chemotherapy* 2002;49:345-51.
26. Maesaki S, Kohno S, Kaku M, et al. Effects of antifungal agent combinations administered simultaneously and sequentially against *Aspergillus fumigatus*. *Antimicrobial Agents and Chemotherapy* 1994;38(12):2843-45.
27. Nguyen MH, Barchiesi F, McGough DA, et al. In vitro evaluation of combination of fluconazole and flucytosine against *Cryptococcus neoformans* var. *neoformans*. *Antimicrobial Agents and Chemotherapy* 1995;39(8):1691-95.
28. Perea S, Gonzalez G, Fothergill AW, et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of *Aspergillus* spp. *Antimicrobial Agents and Chemotherapy* 2002;46(9):3039-41.
29. Schwarz P, Dromer F, Lortholary O, et al. In vitro interaction of flucytosine with conventional and new antifungals against *Cryptococcus neoformans* clinical isolates. *Antimicrobial Agents and Chemotherapy* 2003;47(10):3361-64.
30. Shalit I, Shadkchan Y, Samra Z, et al. In vitro synergy of caspofungin and itraconazole against *Aspergillus* spp.: MIC versus minimal effective concentration end points. *Antimicrobial Agents and Chemotherapy* 2003;47(4):1416-18.
31. Hossain MA, Reyes GH, Long LA, et al. Efficacy of caspofungin combined with amphotericin B against azole-resistant *Candida albicans*. *Journal of Antimicrobial Chemotherapy* 2003;51:1427-29.
32. Polak A, Scholer HJ, Wall M. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. *Chemotherapy* 1982;28:461-79.
33. Sugar AM, Hitchcock CA, Troke PF, et al. Combination therapy of murine invasive candidiasis with

References (continued)

- fluconazole and amphotericin B. *Antimicrobial Agents and Chemotherapy* 1995;39(3):598-601.
34. Polack A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis, and wangielliosis in mice. *Chemotherapy* 1987;33:381-95.
 35. Larsen RA, Bauer M, Thomas AM, et al. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. *Antimicrobial Agents and Chemotherapy* 2004;48(3):985-91.
 36. Van Cutsem J. Therapy of experimental meningeal and disseminated cryptococcosis. *Mycoses* 1993;36:357-67.
 37. Nguyen MH, Najvar LK, Yu CY, et al. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. *Antimicrobial Agents and Chemotherapy*. 1997;41(5):1120-23.
 38. Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. *Antimicrobial Agents and Chemotherapy* 2002;46(8):2564-68.